Chau Nguyen, MD
Cardiovascular Disease · Pasadena, TXNPI 1639149453
Payments from drug & device makers
Across 258 payments — averaging $29.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$2K
- Abbott$1K
- AstraZeneca$1K
- Medtronic$980
- Gilead$367
- Esperion Therapeutics, Inc.$342
- plus $2K from 23 others
What the payments were for
- Travel & lodging$1,45419%
- Food & beverage$5,70975%
- Education$4015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 120 | $1,600 |
| Abbott | 7 | $1,104 |
| AstraZeneca | 25 | $1,044 |
| Medtronic | 10 | $980 |
| Gilead | 4 | $367 |
| Esperion Therapeutics, Inc. | 15 | $342 |
| Johnson & Johnson | 8 | $249 |
| Boston Scientific | 6 | $243 |
| Novartis | 13 | $239 |
| Novo Nordisk | 3 | $162 |
| Inari Medical, Inc. | 1 | $142 |
| Bayer | 1 | $138 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $122 |
| Merck | 7 | $119 |
| Boehringer Ingelheim | 7 | $110 |
| Sanofi-aventis U.S. LLC | 6 | $99 |
| Biogen | 1 | $95 |
| Pfizer | 3 | $62 |
| Lilly USA, LLC | 4 | $61 |
| Amgen | 3 | $56 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| GSK | 2 | $39 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Philips North America LLC | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Agepha Pharma FZ LLC | 1 | $16 |
| Teleflex LLC | 1 | $14 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$705
- Micra$669
- FARXIGA$374
- Vascepa$261
- ABSOLUTE PRO$174
- WATCHMAN Access System$159
- FLOWTRIEVER CATHETER, S$142
- CT THROMBECTOMY SYSTEM KIT$142
- FREESTYLE LIBRE 3$140
- Kerendia$138
- XARELTO$125
- WAINUA$122
- NEXLETOL$121
- Vemlidy$109
- LifeVest$108
How this compares
$7,564 in reported general payments places this provider in the 65th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 565 | $695,448 |
| VascepaIcosapent Ethyl | 467 | $356,128 |
| JardianceEmpagliflozin | 176 | $249,433 |
| RybelsusSemaglutide | 94 | $171,239 |
| XareltoRivaroxaban | 120 | $151,040 |
| EntrestoSacubitril/Valsartan | 109 | $133,634 |
| Ranolazine ErRanolazine | 472 | $120,803 |
| EliquisApixaban | 88 | $97,085 |
| BrilintaTicagrelor | 93 | $94,266 |
| KerendiaFinerenone | 58 | $73,140 |
| NexlizetBempedoic Acid/Ezetimibe | 29 | $24,079 |
| Icosapent Ethyl | 81 | $22,137 |
| DapagliflozinDapagliflozin Propanediol | 38 | $21,967 |
| MultaqDronedarone Hcl | 11 | $21,311 |
| VemlidyTenofovir Alafenamide | 12 | $20,169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $1,044 | $789,713658 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $110 | $255,156189 claims |
| Novo NordiskRybelsus | $162 | $171,23994 claims |
| Johnson & JohnsonXarelto | $249 | $151,040120 claims |
| NovartisEntresto | $239 | $133,634109 claims |
| PfizerEliquis | $62 | $97,08588 claims |
| BayerKerendia | $138 | $73,14058 claims |
| MerckJanuvia, Zontivity | $119 | $27,73526 claims |
| Esperion Therapeutics, Inc.Nexlizet | $342 | $24,07929 claims |
| Sanofi-aventis U.S. LLCMultaq | $99 | $21,31111 claims |
| GileadVemlidy | $367 | $20,16912 claims |
| AmgenCorlanor | $56 | $9,96112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Pasadena
- Karan BhallaPasadena$1.7M
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.